Vistagen Therapeutics, Inc. (VTGN)

Market Cap	22.24M -73.1%
Revenue (ttm)	721,000 -17.7%
Net Income	-62.24M
EPS	-1.92
Shares Out	39.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,739,802
Open	0.5130
Previous Close	0.5050
Day's Range	0.5037 - 0.5658
52-Week Range	0.5028 - 5.1400
Beta	0.30
Analysts	Hold
Price Target	0.90 (+59.8%)
Earnings Date	Feb 12, 2026

About VTGN

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: VTGN
• Website: https://www.vistagen.com

Financial Performance

In fiscal year 2025, Vistagen Therapeutics's revenue was $486,000, a decrease of -54.32% compared to the previous year's $1.06 million. Losses were -$51.42 million, 75.1% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for VTGN stock is "Hold." The 12-month stock price target is $0.9, which is an increase of 59.80% from the latest price.

Price Target

$0.9

(59.80% upside)

Analyst Consensus: Hold